{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Enlivex Therapeutics Ltd."},"Symbol":{"label":"Symbol","value":"ENLV"},"Address":{"label":"Address","value":"14 EINSTEIN STREET, NES ZIONA, 7403618, Israel"},"Phone":{"label":"Phone","value":"+972 26208072"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms."},"CompanyUrl":{"label":"Company Url","value":"https://www.enlivex.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dror Mevorach","title":"Chief Scientific & Medical Officer"},{"name":"Oren Hershkovitz","title":"Chief Executive Officer"},{"name":"Veronique Amor-Baroukh","title":"Senior Director-Operations"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}